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Abstract
Background: Patients with advanced cancer suffer from cachexia, which is characterised by a
marked weight loss, and is invariably associated with the presence of tumoral and humoral factors
which are mainly responsible for the depletion of fat stores and muscular tissue.
Methods: In this work, we used cytotoxicity and enzymatic assays and morphological analysis to
examine the effects of a proteolysis-inducing factor (PIF)-like molecule purified from ascitic fluid of
Walker tumour-bearing rats (WF), which has been suggested to be responsible for muscle atrophy,
on cultured C2C12 muscle cells.
Results: WF decreased the viability of C2C12 myotubes, especially at concentrations of 20–25µg.mL-1. There was an increase in the content of the pro-oxidant malondialdehyde, and a decrease
in antioxidant enzyme activity. Myotubes protein synthesis decreased and protein degradation
increased together with an enhanced in the chymotrypsin-like enzyme activity, a measure of
functional proteasome activity, after treatment with WF. Morphological alterations such as cell
retraction and the presence of numerous cells in suspension were observed, particularly at high
WF concentrations.
Conclusion: These results indicate that WF has similar effects to those of proteolysis-inducing
factor, but is less potent than the latter. Further studies are required to determine the precise role
of WF in this experimental model.
Background
The most common manifestation of advanced malignant
disease is the development of cancer cachexia, which is a
strong independent cause of mortality in this disease [1].
The abnormalities associated with cancer cachexia include
anorexia, loss of body weight and muscle mass, as well as
alterations in carbohydrate, lipid, and protein metabo-
lism [2,3].
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catabolism (hypercatabolism) and decreased protein syn-
thesis (hypoanabolism), both of which may occur simul-
taneously and result in intense muscular atrophy [4,5].
Cytokines, particularly TNF-α, IL-6, and interferon-γ, have
been suggested to be responsible for the metabolic
changes associated with tissue loss in cancer wasting [6-8].
In addition to humoral factors, tumour-derived molecules
have also been proposed as mediators of cancer cachexia.
Todorov et al. [9] purified and characterised a 24 kDa sul-
phated glycoprotein from the cachexia-inducing MAC16
tumour and similar material was also isolated from the
urine of cachectic patients [9]. When this material was
purified and injected into mice it produced a profound
decrease in body weight, which was entirely due to loss of
lean body mass [10]. Atrophy of skeletal muscle was due
to a depression in protein synthesis (by 50%) and an
increase in protein degradation (by 50%) [5]. The mate-
rial was named proteolysis-inducing factor (PIF), because
of its ability to directly induce protein loss in murine myo-
tubes and isolated muscle preparations, and because this
was the name given to an unidentified factor in human
serum, which was capable of inducing proteolysis in iso-
lated muscle preparations [11]. PIF induces protein degra-
dation in skeletal muscle by induction of the ubiquitin-
proteasome proteolytic pathway, which is considered to
be the major mechanism by which myotubular proteins
are degraded in skeletal muscle [12]. Recent results [13]
show that PIF inhibits protein synthesis and induces pro-
tein degradation in skeletal muscle through a single step:
the activation of the ds RNA-dependent protein kinase
(PKR) [13]. Activation of PKR leads to phosphorylation of
eukaryotic initiation factor 2 (eIF2) on the α-subunit,
which inhibits translation initiation by competing with
the guanine nucleotide exchange factor (eIF-2B) for the
exchange of GDP for GTP on eIF2. Activation of PKR also
leads to activation of the transcription factor NF-κB,
which is responsible for the increased expression of major
components of the ubiquitin-proteasome pathway. PIF
may act alone or together with host or tumour derived
cytokines to produce a cachectic state [14]. Both biochem-
ical [15] and histological analysis [16] support the notion
that tumours are the source of PIF.
Tumour growth induces marked changes in the oxidative
metabolism of distant tumour-free tissues and organs of
the host [17]. These changes include an increase in the
level of pro-oxidant compounds and a reduction in the
activities of antioxidant enzymes in extra-tumoral tissues
[18]. A better understanding of the role of cytokines and
tumour factors [19], in the molecular mechanisms of pro-
tein wasting in skeletal muscle is essential for the design
of therapeutic strategies in the near future. The Walker-
256 tumour has been extensively used as an experimental
model to induce cachexia in rats [20], but there have been
no studies on whether the tumour and/or host cells pro-
duce a factor similar to PIF. In this study, we investigated
the metabolic effects of 'Walker factor' (WF) purified from
ascitic fluid from rats bearing the Walker 256 tumour, and
its relationship to PIF.
Methods
Animals and tumour implantation
Adult male Wistar rats were obtained from the Multidisci-
plinary Centre for Biological Investigation (CEMIB) at
UNICAMP. The rats were maintained on a 12 h light/dark
cycle at 23°C and fed standard rodent chow. All of the
experimental protocols involving animals were reviewed
and approved by the Institutional Committee for Ethics in
Animal Experimentation (CEEA/IB/UNICAMP, protocol
no. 342-1). Walker 256 cells were cultured intraperito-
neally and the ascitic fluid was obtained from the perito-
neal cavity as described by Gomes-Marcondes et al. [21].
"Walker factor" purification
The ascitic fluid obtained from Walker 256 tumour-bear-
ing rats was centrifuged to remove the tumour cells and
the high molecular weight proteins of the supernatant
were precipitated with 40% ammonium sulphate and
centrifuged (3000 × g). The supernatant was dialysed with
PBS to remove the ammonium sulphate and then concen-
trated by filtration through an Amicon Ultra centrifugal
filter, 10,000 MW cut off (Millipore Corporation, USA)
prior to concentration by affinity chromatography [9].
The total protein was measured by a colorimetric method
[22]. The 24 kDa protein present in the protein concen-
trate from Walker tumour ascitic fluid (WF) was resolved
by 12% SDS-polyacrylamide gel electrophoresis, stained
by Amido Black (1%) and further quantified by western
blotting using an antibody to PIF (purified by Cancer
Research Laboratory, Aston University, Birmingham, UK).
No protease activity was found in the Walker factor after a
zymography assay; using electrophoresis in the presence
of SDS in 10% polyacrylamide gels and 1 mg/ml gelatin,
the Walker factor protein was renatured by exchanging
SDS and incubated for 22 hours in Tris-HCl buffer (50
mmol/L), followed by Coomassie Blue staining and den-
sitometric analysis.
Cell culture
C2C12 myoblasts, obtained from the Cancer Research Lab-
oratory, Aston University, Birmingham, UK, were grown
in 75 cm2 tissue culture flasks (Corning, NY) at 37°C in a
humidified 5% CO2 atmosphere in medium (DMEM;
Sigma, St. Louis, MO) supplemented with 10% foetal calf
serum (FCS; Sigma) and 1% penicillin/streptomycin
(Sigma). All experiments were initiated using cells grown
to 90–100% confluence. To induce differentiation, the
growth medium was replaced by medium supplemented
with 2% horse serum. 'Walker factor' was incubated withPage 2 of 11
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5, 10, 15, 20 and 25 µg.mL-1.
Cytotoxicity assays
The cell viability of control and WF-treated C2C12 myo-
tube cultures was assessed based on MTT reduction, neu-
tral red uptake (NRU) and nucleic acid content (NAC).
The MTT assay is a sensitive, quantitative colorimetric
assay that measures cell viability based on the capacity of
mitochondrial succinyl dehydrogenase in living cells to
convert the yellow substrate (3-(4,5-dimethylthiozol-2-
yl)-2,5-diphenyltetrazolium bromide, MTT; Sigma) into a
dark blue formazan product. After incubation with a
0.01% solution of MTT for 10 min at 37°C, the medium
was removed and the formazan solubilised in ethanol.
The plate was shaken for 30 min and the absorbance was
measured at 570 nm [23]. The NRU assay is a cell viability
test based on the incorporation of dye into the lysosomes
of viable cells after incubation with the test agents. After
removing the medium from the plates, a 0.05% solution
of neutral red was added to each well followed by incuba-
tion for 3 h at 37°C. The cells were then washed with
phosphate-buffered saline containing calcium (PBS-
Ca2+), followed by the addition of a solution of 1% glacial
acetic acid in 50% ethanol to fix the cells and extract the
neutral red incorporated into the lysosomes. The plates
were shaken for 20 min and the absorbance was measured
at 540 nm [24]. The NAC was determined in the same
plates used for the NRU assay. The cell monolayer was sol-
ubilised with 0.5 N NaOH at 37°C for 1 h after which the
absorbance was measured at 260 nm and expressed as a
percentage of the control [25].
Analytical methods
After 24, 48 and 72 h of treatment, the cells were washed
in cold PBS to slow biochemical reactions, and then col-
lected in homogenising buffer (HB) (20 mM Tris, 1 mM
DTT, 2 mM ATP and 5 mM MgCl2, pH 7.2), and centri-
fuged at 10,000 rpm for 15 min at 4°C. Aliquots of the
homogenate supernatant were analysed for glutathione-S-
transferase (GST) activity based on the conjugation of 1-
chloro-2,4-dinitrobenzene (CDNB; Sigma) with glutath-
ione, and the activity was expressed as nmol.µg protein-
1.min-1, using an extinction coefficient of 9.6, as described
by Habig et al [26]. The lipid peroxidation product
malondialdehyde (MDA) was determined by incubation
with MPO (n-methyl-2-phenylindole; Sigma), followed
by measurement of the absorbance at 590 nm, and the
results were expressed as nmol.µg protein-1 [27]. The chy-
motrypsin-like activity was determined by incubating 10
µL of the homogenate supernatant with 100 µL of the
fluorogenic substrate succinyl-Leu-Leu-Val-Try-7-amino-
4-methylcoumarin (Suc LLVY-AMC) (0.167 µg.µL-1 in
Tris-HCl, pH 7.4), followed by measurement of the fluo-
rescence (excitation: 360 nm, emission: 460 nm), with the
results being expressed as fluorescence.µg protein-1.
Measurement of total protein synthesis and degradation
Differentiated myotubes used for protein synthesis were
grown to confluence then treated with WF (3, 5, 10, 15, 20
and 25 µg.mL-1) for 24, 48 and 72 h. After each treatment
period, the cells were analysed for protein synthesis using
procedures adapted from White et al [28] with the follow-
ing modifications: the myotubes were labelled with L-
[2,63H] phenylalanine (0.67 µCi.mmol-1 in DMEM
added with cold phenylalanine (2 mmol.L-1) for 1 h. Sub-
sequently, the cells were washed twice with 10% TCA, and
then were removed from the plates and centrifuged. The
cellular pellet was prepared by protein precipitation with
10% TCA, which was removed, and 0.5 M NaOH was
added, together with 0.1% Triton, and the incubation was
carried out for 2 h at 37°C. The protein bound radioactiv-
ity was determined in 6 mL scintillation fluid, and
expressed as CPM.µg protein-1.
The myotubes were analysed for protein degradation
using procedures from Gomes-Marcondes et al [12]. Dif-
ferentiated myotubes grown in six-well plates were
labelled with L-[2,63H] phenylalanine (0.67 µCi.mmol-1
in DMEM added with cold phenylalanine 2 mmol.L-1) in
2 mL DMEM containing 2% horse serum. After 24 h, the
myotubes were washed three times in PBS, followed by
the addition of fresh DMEM without phenol red, and then
the cells were subsequently treated with WF (3, 5, 10, 15,
20 and 25 µg.mL-1) for 24, 48 and 72 h. The protein deg-
radation was determined measuring the radioactivity of
the cell supernatant released into the medium using a
Beckmam LS 6000TA liquid scintillation counter, and
expressed as CPM per µg of cellular protein.
Light and scanning electron (SEM) microscopy
C2C12 myotubes were grown on coverslips and treated
with different concentrations of WF. After 24 h of treat-
ment, the cells were analysed by light microscopy (Leica
Instruments). Some cells were fixed in 2.5% paraformal-
dehyde/glutaraldehyde (Sigma) in 0.1 M PBS, pH 7.4, and
then washed in PBS followed by post-fixation with 1%
osmium tetroxide (Sigma) and dehydration in a graded
ethanol series. The cells were subsequently dried to the
critical point (CPDO030 – Balzers, BAL-TEC AG, Wies-
baden, Germany) and gold sputtered (SCD050 – Balzers)
before being analysed in a scanning electron microscope
(JSM-5800LV, JEOL, Peabody, MA, USA) operated at 1 kV.
Statistical analysis
The results were expressed as the mean ± SEM. One-way
ANOVA followed by Bonferroni's test was used to com-
pare the WF-treated groups with the controls [29]. A value
of P < 0.05 indicated significance.Page 3 of 11
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The present work shows that it is possible to purify and
detect the presence of a factor, named here as the "Walker
Factor"(WF), isolated from ascitic fluid of Walker 256
tumour-bearing rats. The WF appears immunologically
identical with PIF (Figure 1), and has the same molecular
weight (24 kDa). The WF was purified by affinity chroma-
tography using anti-PIF antibody and represented around
1.2% of the total protein, after the concentration. Further
the WF was resolved as a single band by SDS-PAGE elec-
trophoresis (Figure 1A) and further detected by Western
blotting using a murine antibody to PIF which detects the
oligosaccharide chains on the glycoprotein (Figure 1B).
To determine whether the WF could have effects similar to
PIF, we used the MTT, NRU and NAC assays to examine
the effects of WF on C2C12 myotubes after treatment with
various concentrations of WF (up to 25 µg.mL-1) for 24,
48 and 72 h. Although the WF has a molecular weight
similar to PIF [9,30] the doses required to produce detect-
able physiological effects are higher than those for PIF
[12,13]. The present results showed that WF was cytotoxic
to cultured C2C12 myotubes at higher concentrations than
PIF. The cell viability decreased after 24 h incubation with
a WF concentration of 25 µg.mL-1; after 48 h and 72 h, WF
affected the cell viability mainly at concentrations of 20–
25 µg.mL-1 (Figure 2A). The cellular lysosomal response
was also significantly affected at high WF concentrations
(20 and 25 µg.mL-1), particularly after 48 h and 72 h (Fig-
ure 2B). The NAC decreased in cells treated with 10 and
25 µg of WF.mL-1, especially after 72 h (Figure 2C), a find-
ing corroborated by the MTT and NRU assays.
Treatment with low concentrations of WF (5–10 µg.mL-1)
for 24 h reduced the GST activity of C2C12 cells, and this
decrease was particularly pronounced after 72 h (Figure
3A) In contrast, there was a significant increase in the
MDA levels at WF concentrations of 5 µg.mL-1 and 10
µg.mL-1 (2.0 and 2.8 times higher than in control cells,
respectively) (Figure 3B).
All concentrations of WF (1 to 25 µg.mL-1) increased the
'chymotrypsin-like' enzyme activity of C2C12 myotubes
after 24 h, and a further increase was observed especially
in 3, 5 and 10 µg.mL-1 after 48 h; the 'chymotrypsin-like'
enzyme activity remained enhanced in all concentrations
Detection of WF after the purification of ascitic fluid from Walker tumour-bearing ratsFigure 1
Detection of WF after the purification of ascitic fluid from Walker tumour-bearing rats. A – pure ascitic fluid (As) and purified 
WF were loaded (10 µg protein) in 12% SDS-polyacrylamide gel followed by 1% Amido Black staining. B – samples of pure 
ascitic fluid (As) and purified WF were resolved by SDS-PAGE on 12% gels followed by Western blotting; the WF expression 
were analysed by probing 0.45 mm enhanced chemical luminescence (ECL) nylon membranes with biotinylated anti-PIF anti-
body (diluted 1:150) followed by detection with the secondary antibody streptavidin horse radish HRP-labelled (dilution 
1:1000). Images of the stained and Western blot gels were captured (FTI 500 Image Master VDS, Pharmacia Biotech). Legend: 
As – pure ascitic fluid, WF – Walker factor obtained by purification and concentration of ascitic fluid, M – marker (220 to 14 
kDa).Page 4 of 11
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of proteins (Figure 4A). The chymotrypsin activity was
suppressed when the C2C12 myotubes were treated with
10 µM lactacystin (a proteasome inhibitor) together with
WF (data not shown). In contrast, WF (only at 10 and 15
µg.mL-1) reduced the protein synthesis in C2C12 myotubes
after 24 h (Figure 4B), with a tendency to a decrease in
protein synthesis at all concentrations. The protein syn-
thesis inhibition was statistically significant and greater at
all WF concentrations and with longer treatments (48 h
and 72 h) (Figure 4B). The WF induced an enhancement
in protein degradation in C2C12 myotubes, in 3, 10, 15. 20
and 25 µg.mL-1, after 24 h, and this was maintained up to
72 h treatment (Figure 4C).
Light and scanning electron microscopy showed that WF
produced morphological changes. Light microscopy
showed that C2C12 myotubes grown in complete medium
in the absence of WF had a normal, elongated shape (Fig-
ure 5A). However, after 24 h incubation with WF (5, 10,
15, 20 and 25 µg.mL-1), morphological changes such as a
loss of cell-to-cell contact and subsequent detachment,
cell retraction and an altered cell shape were observed
(Figure 5B–E). The loss of cell-cell contact was particularly
evident at a high concentration (25 µg.mL-1) of WF (Fig-
ure 5E). Morphological changes were also seen in SEM
after incubation with 1, 3, 5, 10, 15, 20, and 25 µg of
WF.mL-1 for 24 h. Compared to untreated (control) cells
(Figure 6A), treatment with WF resulted in numerous
membrane vesicles and cell detachment, with cell retrac-
The influence of WF on C2C12 cell viability assessed by the MTT reduction (A, absorbance nm), NRU (B, absorbance nm) and NAC (C, absorbance nm) assaysFigure 2
The influence of WF on C2C12 cell viability assessed by the MTT reduction (A, absorbance nm), NRU (B, absorbance nm) and 
NAC (C, absorbance nm) assays. C2C12 myotubes were treated with WF (3, 5, 10, 15, 20 and 25 µg.mL-1) for 24 h, 48 h and 
72 h.
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BMC Cancer 2008, 8:24 http://www.biomedcentral.com/1471-2407/8/24tion leading to changes in cell shape. There was also
strong evidence of collagen matrix degradation (Figure
6B–E). All these confirmations together were seen espe-
cially at high concentrations of WF (Figure 6F and 6H).
The morphological alterations induced by WF resulted in
irreversible cell damage and wasting.
Discussion
Cancer-cachexia may be defined as a severe state of mal-
nutrition, characterised by anorexia, weight loss, muscle
wasting, and anaemia. Although cachexia often involves a
reduced food intake, it differs from starvation in that there
is also evidence of metabolic changes in response to
cytokines or humoral factors produced by the host [11] or
by tumour cells [9] that act directly on skeletal muscle to
reduce protein synthesis or increase proteolysis. The
present work shows for the first time that a PIF-like mole-
cule has been detected in the ascitic fluid from Walker
tumour-bearing rat. This is the first report of a PIF-like
molecule from a tumour-bearing rat, although it has pre-
viously been identified in tumours from both mice [9]
and humans [15]. The WF has both immunological and
molecular weight characteristics identical to PIF, although
it appears to be less potent in inducing a biological
response. PIF shows activity in the nM range [9,13]
whereas the WF requires concentrations up to 1 µM for
maximal biological effect. The reason for this difference is
not known, but could be due to small differences in the
composition of the oligosaccharide chains, which are
essential for the biological activity of PIF [31].
Patients with cancer-induced weight loss show reduced
protein synthesis in skeletal muscle [32] and increased
protein degradation, with the latter resulting from an
increased expression of the ubiquitin-proteasome proteo-
lytic pathway, the major determinant of protein degrada-
tion. In agreement with this, skeletal muscle from
cachectic cancer patients shows increased expression of
mRNA for ubiquitin [33] and the proteasome subunits
[34] with proteasome-mediated proteolytic activity
increasing in parallel with ubiquitin expression [33]. As in
cancer cachexia, there was a marked increase in chymot-
The influence of WF on the glutathione-S-transferase activity (A, nmolFigure 3
The influence of WF on the glutathione-S-transferase activity (A, nmol.min-1.µg protein-1) and malondialdehyde content (B, 
µg.µL-1) of C2C12 myotubes treated with WF (3, 5, 10, 15, 20 and 25 µg.mL-1) for 24 h, 48 h and 72 h.
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BMC Cancer 2008, 8:24 http://www.biomedcentral.com/1471-2407/8/24rypsin-like enzyme activity, the major catalytic activity of
the 20S β proteasome catalytic subunit, [35], in myotubes
after treatment with WF. Protein degradation was
enhanced in C2C12 myotubes treated with WF, in parallel
to an intense depression of protein synthesis, as observed
in skeletal muscle of cachectic cancer patients.
The Walker-256 tumour is an experimental model of can-
cer-cachexia [20] and produces marked changes in the
plasma levels of hormones and cytokines [36-39] includ-
ing WF isolated from the ascitic fluid from tumour-bear-
ing animals, as studied here. Although few studies have
examined the humoral factors produced by Walker
tumour-bearing rats, the present work observed for the
first time that WF has comparable molecular weight and
immunogenicity as PIF and has been shown to produce
similar effects [9] but at higher concentrations. Although
there have been no direct measurements of WF in tumour
tissue, in analogy with other studies [15,16] it could be
produced by the Walker-256 tumour cells and/or host tis-
sue cells as in other study showed that the original PIF
core-protein was also expressed in non-tumour cells
assessed in patients with oesophageal carcinoma [40]. PIF
is a complex sulphated glycoprotein with a short core pep-
tide chain to which is attached both N- and O-linked oli-
gosaccharide chains [31]. Over 80% of the molecule is
carbohydrate. Although mRNA for the PIF core peptide is
upregulated in both tumour and adjacent normal tissue in
gastro-oesophageal malignancy, this does not relate to
prognosis or cachexia [40]. This is because the biological
The influence of WF on the chymotrypsin-like activity (A, % arbitrary intensity of the control µg protein-1), protein synthesis (B, CPM.µg cellular protein-1) and p otei  degr dation (C, CPM.µg protei -1) in C2C12 myotubes incubated with WF (3, 5, 10, 15, 20 and 25 µg.mL-1) for 24 h, 48 h and 72 hFigure 4
The influence of WF on the chymotrypsin-like activity (A, % arbitrary intensity of the control µg protein-1), protein synthesis 
(B, CPM.µg cellular protein-1) and protein degradation (C, CPM.µg protein-1) in C2C12 myotubes incubated with WF (3, 5, 10, 
15, 20 and 25 µg.mL-1) for 24 h, 48 h and 72 h.
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BMC Cancer 2008, 8:24 http://www.biomedcentral.com/1471-2407/8/24activity of PIF is due to the complex oligosaccharide
chains [31]. Thus post-translational modification of the
PIF core peptide is a key step in determining the biological
role, and evidence to date suggests that this can only be
carried out by tumour tissue.
The humoral factors play an important role in the intense
catabolism of carbohydrates, lipids and protein seen in
cancer cachexia [36,41,42]. Vasopressin, prostaglandin E2
and TNF-α have been proposed to be involved in the
development of cancer cachexia in Walker-256 tumour-
bearing rats [35,36]. The infusion or injection of cytokines
into animals decreases the protein content of skeletal
muscle by increasing the rate of protein degradation and
decreasing the rate of protein synthesis [43]. Similar
responses were seen here using cultured C2C12 myotubes.
Tumour-bearing animals can present changes in the activ-
ities of oxidant and antioxidant enzymes that influence
the antioxidant capacity of skeletal muscle and may lead
to oxidative stress [12]. Previous studies have shown
decreased catalase activity in the liver and kidneys of
tumour-bearing rats [44,45]. In the plasma of cancer
patients, there are also marked changes in the activities of
antioxidant enzymes [46]. These changes have been
attributed to an increase in TNF-α that reduces hepatic cat-
alase activity [46]. Glutathione peroxidase and transferase
are the major enzymes involved in protection against cells
peroxidative damage [47]. In addition to a possible con-
trol by hormones and cytokines, reactive oxygen species
(ROS) may also regulate the activity of antioxidant
enzymes [48]. In the present study, WF, especially at high
concentrations, was extremely cytotoxic, as shown by the
decrease in NAC (which reflects a decrease in DNA con-
tent). Additionally, the reduced GST activity seen mainly
after 48 h and 72 h of treatment indicated a loss of cellular
protective mechanisms and increased in oxidative stress as
expressed as malondialdehyde content 24 h after WF
treatment, inducing a cumulative damage on myotubes.
These results agree with those of Tang et al. [49], who
demonstrated that metabolites of the lipoxygenase (12-
LOX) pathway were involved in the survival of Walker
cells by protecting against the increase in lipid peroxida-
tion and the loss of glutathione-S-transferase activity.
Treatment with WF produced morphological changes in
C2C12 myotubes that involved disruption of the collagen
matrix and the loss of cellular adherence, events sugges-
tive of physiological changes associated with pro-
grammed cell death (apoptosis). Although apoptosis has
been widely studied in a variety of tissues in recent years,
the importance of this phenomenon in skeletal muscle
and heart in individuals with cancer has been relatively
ignored. Nevertheless, apoptosis has an important role in
specific cardiac pathologies, particularly in response to
ischemia-perfusion in which ROS are formed. In skeletal
muscle, very few studies have been done under specific
physiological (e.g., exercise) and pathophysiological (e.g.,
dystrophies, denervation, myopathies) conditions. Skele-
tal muscle is unique in that it is multi-nucleated and can
undergo individual myonuclear apoptosis as well as com-
plete cell death [50]. Meanwhile, WF may affect the mor-
phological integrity of the C2C12 myotubes, especially the
matrix collagen by the activation of NF-κB which induces
the stimulation of matrix metalloproteinases [51] in addi-
tion to the ubiquitin-proteasome pathway. PIF induces
degradation of I-kappaBalpha and nuclear accumulation
of NFκB in myotubes enhancing the protein degradation
[52]. Therefore this fact could be involved in the degrada-
tion of the cell matrix and altering the normal cell activi-
ties, thereby leading to cell death. Further experiments are
underway to determine how WF may cause this damage in
C2C12 myotubes.
Light microscopy of C2C12 myotubes treated with WF (5, 10, 15, 20, 25 µg.mL-1 for 24 h)Fi ure 5
Light microscopy of C2C12 myotubes treated with WF (5, 10, 
15, 20, 25 µg.mL-1 for 24 h). A, in the absence of WF, C2C12 
myotubes had a normal, elongated shape. B-F, C2C12 myo-
tubes incubated for 24 h with 5 (B), 10 (C), 15 (D), 20 (E) 
and 25 (F) µg of WF.mL-1. The morphological analysis of WF-
treated C2C12 cells revealed a loss of cell-to-cell contact and 
consequent detachment (white arrows), cell retraction and a 
change in cell shape (arrowheads). Lens 40×.Page 8 of 11
(page number not for citation purposes)
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SEM of C2C12 myotubes treated with WF (5, 10, 15, 20, 25 µg.mL-1 for 24 h)Figure 6
SEM of C2C12 myotubes treated with WF (5, 10, 15, 20, 25 µg.mL-1 for 24 h). A, in the absence of WF, C2C12 myotubes had a 
normal, elongated shape. B-H, C2C12 myotubes incubated for 24 h with 1 (B), 3 (C), 5 (D), 10 (E), 15 (F), 20 (G) and 25 (H) µg 
of WF.mL-1. The morphological analysis of WF-treated C2C12 cells revealed a loss of cell-to-cell contact, with consequent 
detachment and damage to the collagen matrix (arrowheads), cell retraction, altered cell shape and vesicle formation (arrows 
in panel E, F and H). 2500×.
BMC Cancer 2008, 8:24 http://www.biomedcentral.com/1471-2407/8/24Conclusion
Rapid neoplasic growth induces detrimental changes in
the host as a result of carcass wasting. WF may produce its
effects by direct and indirect mechanisms that involve the
inhibition of protein synthesis and increase the protein
degradation associated with an increase in oxidative stress
in C2C12 myotubes, in a manner similar to the host tissue
wastage seen in cancer patients.
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